美国与加拿大对乙酰氨基酚中毒管理:共识声明
美国与加拿大此前无全国性对乙酰氨基酚中毒管理指南,处理差异大。四家临床毒理学学会(America's Poison Centers、American Academy of Clinical Toxicology、American College of Medical Toxicology、Canadian Association of Poison Control Centers)选取21名参与者,由无投票权主席主持,用改良德尔菲法建立决策框架,并系统检索文献、收集多数中毒中心指南,外部机构评审意见纳入后定稿,项目自2021年3月开始至2023年3月结束。检索获得84份指南和278篇文献,形成单次或反复摄入对乙酰氨基酚的急诊科管理推荐,涵盖缓释剂型、高风险摄入、抗胆碱能药或阿片类共摄入、年龄小于6岁、妊娠、体重超过100 kg及静脉对乙酰氨基酚使用。与当前美国实践不同之处包括将急性摄入定义为过量开始后4至24小时就诊,采用修订版Rumack-Matthew列线图,以「高风险摄入」替代「大量摄入」并用特定列线图线标示,另给出急诊分诊、实验室评估与监测参数、胃肠去污作用、乙酰半胱氨酸详细管理及不良反应与停药标准、临床毒理学家会诊标准,以及乙酰半胱氨酸剂量、甲吡唑给药、体外清除和移植评估等具体治疗考虑。
要点
- 急性摄入定义为过量开始后4至24小时就诊,与当前美国实践不同。
- 采用修订版Rumack-Matthew列线图,以「高风险摄入」替代「大量摄入」并用特定列线图线标示。
- 共识覆盖缓释剂型、高风险摄入、抗胆碱能药或阿片类共摄入、年龄小于6岁、妊娠、体重超过100 kg及静脉对乙酰氨基酚使用。
- 推荐涵盖急诊分诊、实验室评估与监测参数、胃肠去污作用、乙酰半胱氨酸详细管理及不良反应与停药标准、临床毒理学家会诊标准。
- 治疗考虑包括乙酰半胱氨酸剂量、甲吡唑给药、体外清除和移植评估。
适用人群与场景
- 美国与加拿大单次或反复摄入对乙酰氨基酚的患者。
- 特殊人群包括:缓释剂型摄入、高风险摄入、抗胆碱能药或阿片类共摄入、年龄小于6岁、妊娠、体重超过100 kg、静脉对乙酰氨基酚使用。
诊断标准与关键阈值
- 急性摄入定义为过量开始后4至24小时就诊。
- 采用修订版Rumack-Matthew列线图。
- 以「高风险摄入」替代「大量摄入」,并由特定列线图线标示。
处置流程与药物剂量
- 急诊分诊、实验室评估与监测参数按共识特定标准执行。
- 胃肠去污的作用按共识界定。
- 乙酰半胱氨酸治疗按共识详细管理,包括不良反应处理与停药标准。
- 乙酰半胱氨酸剂量、甲吡唑给药、体外清除和移植评估按共识具体考虑执行。
- 按共识标准与临床毒理学家会诊。
研究设计与关键结果
- 四家临床毒理学学会选取21名参与者,由无投票权主席主持,采用改良德尔菲法建立决策框架。
- 系统检索获得84份指南和278篇文献,并收集多数中毒中心指南,外部机构评审意见纳入后定稿。
- 项目自2021年3月开始至2023年3月结束。
- 形成的推荐涵盖单次或反复摄入的急诊科管理,以及缓释剂型、高风险摄入、抗胆碱能药或阿片类共摄入、年龄小于6岁、妊娠、体重超过100 kg和静脉对乙酰氨基酚使用。
- 与当前美国实践不同之处包括急性摄入定义(过量开始后4至24小时就诊)、修订版Rumack-Matthew列线图、以「高风险摄入」替代「大量摄入」并用特定列线图线标示。
- 其他推荐包括急诊分诊、实验室评估与监测参数、胃肠去污作用、乙酰半胱氨酸详细管理及不良反应与停药标准、临床毒理学家会诊标准,以及乙酰半胱氨酸剂量、甲吡唑给药、体外清除和移植评估。
证据类型、等级与局限
- 证据类型:共识声明(改良德尔菲法)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊科应将急性摄入定义为过量开始后4至24小时就诊,并采用修订版Rumack-Matthew列线图评估。
- 以「高风险摄入」替代「大量摄入」概念,并用特定列线图线识别高风险患者。
- 对缓释剂型、抗胆碱能药或阿片类共摄入、年龄小于6岁、妊娠、体重超过100 kg及静脉对乙酰氨基酚使用等特殊人群按共识特定考虑处理。
- 按共识标准进行急诊分诊、实验室评估与监测、胃肠去污、乙酰半胱氨酸治疗及停药、临床毒理学家会诊。
指南或共识出处
- Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement(JAMA Netw Open),由America's Poison Centers、American Academy of Clinical Toxicology、American College of Medical Toxicology、Canadian Association of Poison Control Centers共同制定,项目于2021年3月至2023年3月完成。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The US and Canada currently have no formal published nationwide guidelines for specialists in poison information or emergency departments for the management of acetaminophen poisoning, resulting in significant variability in management.
OBJECTIVE: To develop consensus guidelines for the management of acetaminophen poisoning in the US and Canada.
EVIDENCE REVIEW: Four clinical toxicology societies (America's Poison Centers, American Academy of Clinical Toxicology, American College of Medical Toxicology, and Canadian Association of Poison Control Centers) selected participants (n = 21). Led by a nonvoting chairperson using a modified Delphi method, the panel created a decision framework and determined the appropriate clinical management of a patient with acetaminophen poisoning. Unique to this effort was the collection of guidelines from most poison centers in addition to systematic collection and review of the medical literature. Comments from review by external organizations were incorporated before the guideline was finalized. The project began in March 2021 and ended in March 2023.
FINDINGS: The search retrieved 84 guidelines and 278 publications. The panel developed guidelines for emergency department management of single or repeated ingestion of acetaminophen. In addition, the panel addressed extended-release formulation, high-risk ingestion, coingestion of anticholinergics or opioids, age younger than 6 years, pregnancy, weight greater than 100 kg, and intravenous acetaminophen use. Differences from current US practice include defining acute ingestion as an ingestion presentation from 4 to 24 hours after overdose was initiated. A revised form of the Rumack-Matthew nomogram was developed. The term massive ingestion was replaced with the term high-risk ingestion and denoted by a specific nomogram line. Other recommendations include specific criteria for emergency department triage, laboratory evaluation and monitoring parameters, defining the role of gastrointestinal decontamination, detailed management of acetylcysteine treatment, associated adverse effects, and stopping criteria for acetylcysteine treatment, as well as criteria for consultation with a clinical toxicologist. Finally, specific treatment considerations, including acetylcysteine dosing, fomepizole administration, and considerations for extracorporeal elimination and transplant evaluation, were addressed.
CONCLUSIONS AND RELEVANCE: This qualitative study provides a consensus statement on consistent evidence-based recommendations for medical, pharmacy, and nursing education and practice to optimize care of patients with acetaminophen poisoning.
参考来源
- Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open. 2023. PMID: 37552484. doi:10.1001/jamanetworkopen.2023.27739
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。